Rethinking Strategies in Pharma Amidst Supply Chain Disruptions
pharma; supply chain; cost control; capability building
Neuphoria’s Social Anxiety Drug Fails in Phase 3 Trial, Program Discontinued
Neuphoria Therapeutics; BNC210; social anxiety disorder; phase 3 trial; AFFIRM-1; clinical failure; strategic review; PTSD
Exelixis’ Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review
Exelixis; zanzalintinib; kinase inhibitor; colorectal cancer; STELLAR-303 trial; Tecentriq; regorafenib; overall survival; third-line therapy; FDA submission
Iambic’s AI-Designed HER2 Inhibitor IAM1363 Shows Early Anti-Tumor Activity in Heavily Pretreated Patients
Iambic Therapeutics; AI-designed drug; IAM1363; HER2 inhibitor; cancer; clinical trial; Phase 1/1b; ESMO 2025; brain-penetrant; tyrosine kinase inhibitor
Replimune Resubmits Melanoma Drug for FDA Approval After Initial Rejection
Replimune; RP1; Melanoma Treatment; FDA Approval; Resubmission
CatalYm Presents Long-Term Phase 1/2a Data for Visugromab at ESMO 2025
CatalYm; Visugromab; ESMO 2025; CPI-Refractory Tumors; GDF-15
Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress
Clarametyx Biosciences; leadership team; executive promotions; pipeline development; corporate development; Steve St. Onge; Brendan Doran; immune-enabling therapies; biofilm-driven chronic respiratory disease
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
Achieve Life Sciences; Erik Atkisson; Chief Legal Officer; Cytisinicline; FDA Approval
Weight-loss drug stocks drop after Trump pledges major price cuts
weight-loss drugs; ozempic; wegovy; novo nordisk; eli lilly; stock drop; drug pricing; trump administration; GLP-1
Roche’s Giredestrant Advances Oral SERD Debate at ESMO 2025
ESMO 2025; Giredestrant; Roche; Oral SERD; ER-Positive HER2-Negative Breast Cancer